Zacks Small Cap Weighs in on VolitionRx Q3 Earnings

Key Points

• Zacks Small Cap forecasts VolitionRx's Q3 2025 earnings per share (EPS) to be ($0.07), with a full-year estimate of ($0.28) EPS.
• Insider buying was notable as CEO Cameron John Reynolds and Director Guy Archibald Innes each acquired 78,125 shares at $0.64, increasing their ownership significantly.
• The company's stock has a consensus rating of "Buy" with a target price of $3.50, despite recent trading down 3.7% to $0.66.

VolitionRx Limited (NYSE:VNRX - Free Report) - Analysts at Zacks Small Cap issued their Q3 2025 earnings estimates for shares of VolitionRx in a note issued to investors on Monday, August 25th. Zacks Small Cap analyst S. Ralston anticipates that the company will post earnings per share of ($0.07) for the quarter. The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. Zacks Small Cap also issued estimates for VolitionRx's Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.25) EPS.

Other equities analysts have also recently issued reports about the stock. D. Boral Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a research report on Friday, August 15th. Jones Trading raised shares of VolitionRx to a "strong-buy" rating and set a $3.00 price objective for the company in a research report on Tuesday, June 10th. Finally, Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a "sell" rating for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, VolitionRx has a consensus rating of "Buy" and a consensus price target of $3.50.

VolitionRx Price Performance

VNRX stock traded up $0.03 during midday trading on Wednesday, reaching $0.69. 104,343 shares of the company were exchanged, compared to its average volume of 195,261. The business has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $0.60. VolitionRx has a one year low of $0.40 and a one year high of $0.94. The firm has a market capitalization of $74.24 million, a price-to-earnings ratio of -1.92 and a beta of 1.26.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes purchased 78,125 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was acquired at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the director directly owned 966,814 shares in the company, valued at $618,760.96. This trade represents a 8.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Cameron John Reynolds purchased 78,125 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average cost of $0.64 per share, with a total value of $50,000.00. Following the purchase, the chief executive officer owned 2,609,847 shares of the company's stock, valued at $1,670,302.08. This represents a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 188,750 shares of company stock valued at $118,175 in the last three months. Insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VNRX. Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Armistice Capital LLC raised its stake in VolitionRx by 3.5% in the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company's stock valued at $6,455,000 after purchasing an additional 286,644 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRx in the second quarter valued at about $52,000. Millennium Management LLC acquired a new position in VolitionRx in the fourth quarter valued at about $36,000. Finally, Silverberg Bernstein Capital Management LLC raised its stake in VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.